Engenious Design Partners with Precision Microwave

Together They Will Expand Precision Microwave’s Groundbreaking-technology That Treats Previously-Inoperable Cancers

Engenious Design has partnered with Manhattan (KS) startup Precision Microwave to develop a technologically-advanced system to treat previously-inoperable cancer tumors with minimally-invasive surgery.

The system is a new Microwave (MW) Generator to accompany Precision Microwave’s next-generation Directional Microwave Ablation (DMWA) applicator.

Precision Microwave and Engenious Design are combining Precision’s market-disruptive technology with Engenious Design’s experience in medical device design. Precision Microwave’s DWMA system is a new tool for minimally-invasive thermal ablation treatment of cancers, a novel treatment tool with ability to reduce the risk of unintended injury to vital structures near tumors. The new technology complements existing options for thermal ablation and greatly expands the tools available to surgeons that address challenging cases and broaden the range of cases that could be safely and effectively treated.

Austin Pfannenstiel, Precision Microwave’s founder and CEO, explains, “Engenious Design has been the perfect partner for a small, start-up medical device company like us. I have been consistently impressed by their team’s tremendous depth of knowledge and experience spanning technical & industrial design, clinical insight, and regulatory considerations, which has enabled us to stay focused on leveraging our own strengths while making significant progress towards commercialization. Importantly, Engenious Design has always been very considerate of the resource constraints faced by a small start-up and has been invaluable in helping us identify and accomplish milestones that add maximum value.”

Precision Microwave’s system was recently granted a key patent protecting the unique, directional ablation technology. Precision Microwave’s regulatory strategy also employs a faster and lower-risk path to FDA clearance by leveraging predicate devices. Precision Microwave has already received $1.2 MM in grant funding from the National Science Foundation (NSF), and are working to close additional funds to pursue FDA clearance and commercialization.

Chris Justice, Principal at Engenious Design, adds, “Most of us have been affected by cancer through family, friends or our own experience, and we are delighted to help Precision Microwave create better tools to fight cancer. Precision Microwave’s technology is truly innovative and works to provide more precise control to surgeons; control that allows targeting of cancers and preservation of adjacent vital structures. The Precision Microwave team has developed technology that is a game-changer in cancer therapy and we are excited to partner and bring this technology to market quickly.”

About Engenious Design: Kansas City metro based, Engenious Design is a creative product design firm specializing in electronic medical device design. Since its founding in 2013 by spouses Chris and Holly Justice, the Engenious Design team has grown from 2 to 40+ team members. Team expertise includes Electrical, Embedded Software, Mechanical and Test Engineers, Industrial, Interaction, and Graphic Designers, as well as others. Engenious Design capabilities include an on-site electronics lab, quick-turn model shop, and short-run production capabilities with a full medical device quality management system.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”